Jun. 26 at 6:41 PM
$AWKNF $SVNS.L
Initiation of research coverage by Singer Capital Markets
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, is pleased to announce that Singer Capital Markets (“Singers”) has today initiated equity research coverage (the “Initiation Note”) on the Company.
The Initiation Note, titled "Psyching up for success", has been authored by Dr. Karl Keegan, Head of Life Sciences Research at Singers.
The research note is currently available to eligible institutional investors and will be made publicly available via Singers next week.